Deal-Making

Cytiva and Nucleus team on custom cell media for CGTs

The collaboration with Nucleus Biologics will provide transparent and scalable manufacture of custom cell culture media, says Cytiva. Under the terms of the deal, Cytiva and cell culture firm Nucleus Biologics have partnered to develop custom media formulation and fulfillment solutions for the cell and gene therapy (CGT) space. Cytiva customers will be able to formulate their own custom cell culture media through Xuri Media AI Guide, which is based on Nucelus’ NB-AIR platform. Additionally, clients can configure their media…

HPNE to expand single-use capacity on back of $15m BARDA contract

Funding from BARDA gives High Purity New England (HPNE) the opportunity to expand into its fourth facility, the bioprocess vendor says. HPNE has been contracted to produce pharmaceutical consumable equipment for the Biomedical Advanced Research and Development Authority (BARDA) and its third parties, issued in response to a Presidential Declaration of Public Health Emergency. The $15 million contract – number 75A50122C00009 – forms part of the office of the Assistant Secretary for Preparedness and Response at the US Department of…

Novo Nordisk Foundation invests $343m to build stem-cell research center

Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine. The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands. The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa…

CBM and UPenn enter gene therapy manufacturing pact

A five-year deal will see the Center for Breakthrough Medicines (CBM) gain commercial rights to certain gene therapy manufacturing and analytics platforms from the University of Pennsylvania. The King of Prussia, Pennsylvania-based contract development and manufacturing organization (CDMO) has entered a collaboration with the University of Pennsylvania Gene Therapy Program (GTP) to help small biotech firms, universities, and large pharma firms advance gene therapies through the clinic. The collaboration brings CBM access to UPenn’s gene therapy expertise, which has helped…

BioNTech and Crescendo partner to develop precision immunotherapies

The collaboration sees BioNtech combine its multimodal immunotherapy expertise with Crescendo’s Humabody VH platform to produce precision immunotherapies. Crescendo Biologics, a clinical-stage immuno-oncology company developing targeted T cell enhancing therapeutics will contribute its transgenic platform to deliver fully human heavy-chain antibody domains (Humabody VH) against targets selected by BioNTech. This includes messenger RNA (mRNA) based antibodies, as well as engineered cell therapies that have the potential to treat patients with cancer and other diseases. Humabodies are the smallest part of…

TTP and CellFiber partner to ‘revolutionize’ CGTs

TTP’s experience will enable CellFiber’s technology to provide affordable cell production with a higher yield and better product quality, says firm. TTP, a technology and product development firm based in Cambridge, UK, says its experience in designing systems for production at scale and CellFiber’s technology has the potential to revolutionize the manufacture of cell therapies. Stem cell therapy can treat various diseases, including advanced Parkinson’s disease, cancer, diabetes, and heart disease. TTP claims that producing large quantities of these cells is complex, making…

Performance Cell acquired by PE, renamed Cellipont Bioservices

San Diego CDMO Performance Cell Manufacturing has been acquired by private equity firm Great Point Partners and will operate as Cellipont Bioservices.   Performance Cell Manufacturing (PCM), a contract development and manufacturing organization (CDMO) that has manufactured cell therapies for more than fifteen years, has been acquired by Great Point Partners (GPP) for an undisclosed fee. This is the latest move in a series of CDMO investments by GPP, which includes Cytovance Biologics, MaSTherCell (later acquired by Catalent in February…

Danaher: $10bn+ war chest in 2022 but sees no gaps in bioprocessing

Danaher Corporation claims to be the leading player in bioprocessing and hopes to strengthen the offering further in 2022 through opportunist acquisitions. In 2021, Danaher Corporation spent over $10 billion in M&A deals. The bulk of the capital – $9.6 billion – was used to enter the contract development and manufacturing organization (CDMO) through the addition of Aldevron, though other deals in the life sciences space included the addition of lipid nanoparticle tech firm Precision Nanosystems (PNI). And discussing the…

Takeda drives immuno-oncology portfolio with Adaptate buy

The acquisition will add Adaptate’s novel antibody-based delta T-cell engager platform to Takeda’s immune-oncology portfolio. Takeda is set to acquire UK firm Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for the adaptation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. In addition to gaining Adaptate’s antibody-based γδ T cell engager platform, Takeda will also obtain its preclinical candidate and discovery pipeline programs. “Adaptate’s γδ T-cell engagers are engineered to specifically activate a γδ T cell-mediated immune…

Pfizer bolsters mRNA through deals with Acuitas, Codex, and Beam

Pfizer has signaled its intention of taking mRNA beyond COVID-19 through a triad of deals announced on the first day of JP Morgan’s annual healthcare conference. Pfizer has already seen major messenger RNA (mRNA) success with BioNTech and their respective COVID-19 vaccine, BNT162b2 (Comirnaty). Now, the firm has announced its plans at JP Morgan’s healthcare conference to become an mRNA powerhouse through a triumvirate of deals. The deals, described below, see Pfizer team up with Acuitas Therapeutics, Codex DNA, and…